<DOC>
	<DOCNO>NCT02547220</DOCNO>
	<brief_summary>To evaluate efficacy Cinryze® give treatment acute antibody-mediated rejection ( renal allograft ) ( AMR ) kidney transplant recipient measure proportion subject new worsen transplant glomerulopathy ( TG ) 6 month treatment initiation .</brief_summary>
	<brief_title>A Multicenter Study Evaluate Efficacy Safety Cinryze® Treatment Acute Antibody-mediated Rejection Patients With Kidney Transplant</brief_title>
	<detailed_description />
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Complement C1 Inhibitor Protein</mesh_term>
	<mesh_term>Complement C1 Inactivator Proteins</mesh_term>
	<criteria>1 . Be &gt; =18 &lt; =70 year age . 2 . Weigh &gt; =45 kg body mass index ( BMI ) &lt; 35 kg/m^2 screening . 3 . Have HLA DSA identify time diagnosis AMR . If anticipated local DSA result available within screen period , previously obtain local DSA result use assess eligibility , obtain kidney transplant within 30 day prior qualify AMR episode . In instance , local DSA test still perform time AMR diagnosis . 4 . Have first qualify episode AMR subject 's current renal allograft 72 hour 12 month transplant define renal allograft biopsy demonstrate neutrophil and/or monocyte infiltration PTC and/or glomerulus without evidence C4d deposition immunohistopathology accord 2013 Banff criterion . 5 . Have achieve adequate renal function define : PreAMR baseline eGFRMDRD &gt; =20 mL/min/1.72m^2 qualify AMR episode occur &lt; =21 day transplant preAMR baseline eGFRMDRD &gt; =30 mL/min/1.72m^2 qualify AMR episode occur &gt; 21 day transplant . The preAMR baseline high eGFRMDRD value obtain follow kidney transplant within 30 day prior qualify AMR episode . If 1 eGFRMDRD value available , mean 2 high value ( least 1 day apart prior AMR episode ) use preAMR baseline value . If eGFRMDRD obtain within 30 day prior biopsy , evaluate within 60 day period . 6 . Receive first dose investigational product 7 day kidney transplant procedure within 7 day qualify renal allograft biopsy procedure positive AMR . 7 . Be inform nature study provide write informed consent studyspecific procedure perform . 8 . If female childbearing potential , must negative urine pregnancy test confirm negative serum beta human chorionic gonadotropin ( betaHCG ) pregnancy test Screening Visit must negative urine pregnancy test Day 1 visit . 9 . Agree comply applicable contraceptive requirement protocol . 1 . Have receive pediatric en bloc kidney transplant . 2 . Have focal segmental glomerulosclerosis , rapidly progressive glomerulonephritis , membranoproliferative glomerulonephritis type 1 , ( include C3 glomerulopathy ) , `` dense deposit disease '' , thrombotic microangiopathy cause native kidney failure . 3 . Have prior concurrent nonrenal solid organ transplant hematopoietic stem cell transplant ( HSCT ) 2 complete kidney transplant procedure . 4 . Have know neoplastic lesion transplant allograft . 5 . Have , ongoing infection cause hemodynamic compromise determine investigator , surgical medical condition could interfere administration investigational product , interpretation study result , could compromise patient safety , include ( determined transplant surgeon document operative report ) major technical complication renal artery , renal vein , ureteral anastomosis . 6 . Have ongoing treatment HCV infection . 7 . Have recent myocardial infarction ( MI ) transient ischemic attack ( TIA ) within past 6 month . 8 . Have history abnormal bleeding , clot , coagulopathy ( exclude history clot hemodialysis access superficial thrombophlebitis absence medically confirm coagulopathy ) . 9 . Have history allergic reaction CINRYZE blood product . 10 . Have change androgen therapy ( eg , danazol , oxandrolone , stanozolol , testosterone ) , tranexamic acid , epsilonaminocaproic acid , fibrinolytics within 3 month first dose investigational product . 11 . Have participate active dose phase investigational drug study within 30 day prior dose investigational product . 12 . Have follow local laboratory value prior dose investigational product : Within 24 hour prior subject dosing , white blood cell ( WBC ) count &lt; 0.5×10^9/L &gt; 20×10^9/L ( value &gt; 20×10^9/L exclude obtain steroid treatment ) Within 72 hour prior subject dose platelet count &lt; 25×10^9/L &gt; 600×10^9/L 13 . Be pregnant breastfeeding . 14 . Have receive following agent within 1 month prior first dose investigational product : Sucrosecontaining IVIg Any C1 INH ( plasmaderived [ eg , CINRYZE® , Berinert® , Cetor® ] recombinant [ eg , Rhucin® ] ) Eculizumab ( Soliris® ) Ecallantide ( Kalbitor® )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>